Accession Number:



Targeting the CRMP2-Ca2+ Channel Complex for Abortive Treatment of Migraine and Posttraumatic Headache

Descriptive Note:

[Technical Report, Annual Report]

Corporate Author:

University of Arizona

Report Date:


Pagination or Media Count:



Migraine is one of the worlds most common neurological disorders. Current acute migraine treatments have sub-optimal efficacy and new therapeutic options are needed. Approaches targeting calcitonin gene related peptide CGRP signaling are clinically effective but small molecule antagonists have not been advanced due to toxicity. In this study, we explored the axonal growthspecification collapsin response mediator protein 2 CRMP2 as a novel druggable target for inhibiting CGRP release and for potential relevance for treatment of migraine pain and post-traumatic headache. CRMP2 has been demonstrated to regulate N-type voltage gated Ca2 channel CaV2.2 activity and Ca2 -dependent CGRP release in sensory neurons. The co-expression of CRMP2 with CaV2.2 and CGRP in trigeminal ganglia TG sensory neurons suggested the possibility of a novel approach to regulate CGRP release in the trigeminal system.

Subject Categories:

  • Medicine and Medical Research
  • Pharmacology

Distribution Statement:

[A, Approved For Public Release]